Breakthroughs In MASH, With 89bio CEO The Pharma Letter podcast

Artwork

News Simon Wentworth Biotech Pharma Pharmaceutical Editorial Analysis Prescription Drugs Medicine Patient

Innehåll tillhandahållet av Simon Wentworth. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Simon Wentworth eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

The Pharma Letter Podcast »
Breakthroughs in MASH, with 89bio CEO

10d ago 22:19

Dela

MP3•Episod hem

Innehåll tillhandahållet av Simon Wentworth. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Simon Wentworth eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

This week we’re focusing on an area of clinical research that has been of great interest for a number of years, that is NASH, also known as MASH.
It’s a high area of unmet medical need, with over 20 million diagnosed cases across Europe and the USA, and while there are more than 80 therapies currently in the pipeline, only around 5% of these are in Phase III development.
One company working in this area is San Francisco-based 89bio (Nasdaq: ETNB), which has a candidate now in Phase III, pegozafermin, and in this episode we are joined by the company’s chief executive, Rohan Palekar.
We are also joined by Dr Arun Sanyal, who is Professor of Medicine at VCU Health and founder of the Liver Trust.

… continue reading

27 episoder

#News #Simon Wentworth #Biotech #Pharma #Pharmaceutical #Editorial #Analysis #Prescription Drugs #Medicine #Patient

Artwork

Breakthroughs in MASH, with 89bio CEO

The Pharma Letter Podcast

published 10d ago

Dela

MP3•Episod hem

Innehåll tillhandahållet av Simon Wentworth. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Simon Wentworth eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

This week we’re focusing on an area of clinical research that has been of great interest for a number of years, that is NASH, also known as MASH.
It’s a high area of unmet medical need, with over 20 million diagnosed cases across Europe and the USA, and while there are more than 80 therapies currently in the pipeline, only around 5% of these are in Phase III development.
One company working in this area is San Francisco-based 89bio (Nasdaq: ETNB), which has a candidate now in Phase III, pegozafermin, and in this episode we are joined by the company’s chief executive, Rohan Palekar.
We are also joined by Dr Arun Sanyal, who is Professor of Medicine at VCU Health and founder of the Liver Trust.

… continue reading

27 episoder

#News #Simon Wentworth #Biotech #Pharma #Pharmaceutical #Editorial #Analysis #Prescription Drugs #Medicine #Patient

Alla avsnitt

×

Välkommen till Player FM

Player FM scannar webben för högkvalitativa podcasts för dig att njuta av nu direkt. Den är den bästa podcast-appen och den fungerar med Android, Iphone och webben. Bli medlem för att synka prenumerationer mellan enheter.

Lyssna på 500+ ämnen